{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:24:13Z","timestamp":1794263053112,"version":"4.9.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.autrev.2025.103895","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T15:45:10Z","timestamp":1753803910000},"page":"103895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Monoclonal Gammopathy of Rheumatologic Significance (MGRhS): a systemic vision of clonal disorders with multiple organ involvement"],"prefix":"10.1016","volume":"24","author":[{"given":"Luca","family":"Quartuccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Manfr\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Treppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Perrotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaafar","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Goules","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103895_bb0005","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/0002-9343(78)90522-3","article-title":"Monoclonal gammopathy of undetermined significance","volume":"64","author":"Kyle","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0010","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0015","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4065\/mcp.2010.0337","article-title":"Prevalence of monoclonal gammopathy of undetermined significance: a systematic review","volume":"85","author":"Wadhera","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2025.103895_bb0020","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.autrev.2025.103895_bb0025","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103895_bb0030","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0035","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1016\/S2665-9913(21)00348-9","article-title":"Monoclonal gammopathy of clinical significance: what the rheumatologist needs to know","volume":"4","author":"Marinkovic","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0040","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00277-021-04400-7","article-title":"Risk factors for monoclonal gammopathy of undetermined significance: a systematic review","volume":"100","author":"Castaneda-Avila","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.autrev.2025.103895_bb0045","first-page":"28","article-title":"Considerations regarding the pathogenesis of the plasmacytic dyscrasias","volume":"4","author":"Osserman","year":"1965","journal-title":"Ser Haematol"},{"key":"10.1016\/j.autrev.2025.103895_bb0050","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103895_bb0055","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2025.103895_bb0060","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1182\/blood-2011-04-347559","article-title":"Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study","volume":"118","author":"Lindqvist","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103895_bb0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1756-8722-5-59","article-title":"Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma","volume":"5","author":"Hemminki","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2025.103895_bb0070","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1158\/1055-9965.EPI-13-0695","article-title":"Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review","volume":"23","author":"McShane","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.autrev.2025.103895_bb0075","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/ejh.13563","article-title":"Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Baldursd\u00f3ttir","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.autrev.2025.103895_bb0080","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/bloodadvances.2020003193","article-title":"Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma","volume":"5","author":"Steiner","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.autrev.2025.103895_bb0085","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M23-2867","article-title":"Association between autoimmune diseases and monoclonal gammopathy of undetermined significance: an analysis from a population-based screening study","volume":"177","author":"Sverrisdottir","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0515","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/ard.50.5.290","article-title":"Prognostic significance of paraproteinaemia in rheumatoid arthritis","volume":"50","author":"Kelly","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0520","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.mayocp.2022.06.030","article-title":"Risk of hematologic malignancies in elderly patients with ankylosing spondylitis: a cohort study and systematic review","volume":"98","author":"Alehashemi","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2025.103895_bb0525","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.111054","article-title":"Prevalence of monoclonal gammopathy among patients with psoriatic arthritis","volume":"39","author":"Eder","year":"2012","journal-title":"J Rheumatol"},{"issue":"suppl 10","key":"10.1016\/j.autrev.2025.103895_bib591","article-title":"Monoclonal Gammopathy in Psoriatic Arthritis [abstract]","volume":"72","author":"Ocampo","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876271","article-title":"Autoimmunity, infections, and the risk of monoclonal gammopathy of undetermined significance","volume":"13","author":"Sigurbergsd\u00f3ttir","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2025.103895_bb0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.23736\/S0026-4806.20.07158-X","article-title":"Rheumatologic manifestations of Hepatitis C Virus","volume":"112","author":"Treppo","year":"2021","journal-title":"Minerva Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0100","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/S0140-6736(11)60242-0","article-title":"The cryoglobulinaemias","volume":"379","author":"Ramos-Casals","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103895_bb0105","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MD.0b013e318288925c","article-title":"The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases","volume":"92","author":"Terrier","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2025.103895_bb0110","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ajh.26944","article-title":"Prognosis and long-term outcomes in type I cryoglobulinemia: a multicenter study of 168 patients","volume":"98","author":"Ghembaza","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2025.103895_bb0115","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/1744666X.2023.2249609","article-title":"Recent updates in the diagnosis and management of cryoglobulinemic vasculitis","volume":"19","author":"Treppo","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"Suppl. 103","key":"10.1016\/j.autrev.2025.103895_bb0120","first-page":"67","article-title":"HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian Group for the Study of Cryoglobulinaemias (GISC)","volume":"35","author":"Galli","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0125","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.semarthrit.2020.05.004","article-title":"Cryoglobulinemia after the era of chronic hepatitis C infection","volume":"50","author":"Boleto","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103895_bb0130","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103895_bb0135","first-page":"84","article-title":"Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia","volume":"28","author":"Quartuccio","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10067-022-06391-w","article-title":"Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)","volume":"42","author":"Quartuccio","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0145","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.autrev.2011.01.008","article-title":"Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients","volume":"10","author":"Pietrogrande","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103895_bb0150","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.autrev.2019.06.008","article-title":"Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome","volume":"18","author":"Galli","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103895_bb0155","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.transci.2018.06.005","article-title":"Apheresis treatment of cryoglobulinemic vasculitis: a multicentre cohort study of 159 patients","volume":"57","author":"Marson","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.autrev.2025.103895_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103034","article-title":"Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: data from a European collaborative study and review of the literature","volume":"21","author":"Pouchelon","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103895_bb0165","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/hep.32281","article-title":"A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort","volume":"76","author":"Kondili","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0170","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/rheumatology\/key157","article-title":"Late relapses of hepatitis C virus-cured mixed cryoglobulinaemia associated with infection or cancer","volume":"57","author":"Visentini","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0175","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.ekir.2021.01.033","article-title":"Obinutuzumab rescue in rituximab resistant mixed cryoglobulinemia","volume":"6","author":"Genest","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.autrev.2025.103895_bb0180","first-page":"10","article-title":"Mixed Cryoglobulinaemia Vasculitis treated with Obinutuzumab in a patient allergic to rituximab","author":"Gaudencio","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0185","doi-asserted-by":"crossref","first-page":"52","DOI":"10.55563\/clinexprheumatol\/rit83o","article-title":"Flare of a mixed cryoglobulinaemic vasculitis after obinutuzumab infusion","volume":"39","author":"Martin De Fremont","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0190","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3899\/jrheum.190076","article-title":"Rituximab-associated Vasculitis flare: incidence, predictors, and outcome","volume":"47","author":"Desbois","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0195","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jha2.686","article-title":"Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia","volume":"4","author":"Jamali","year":"2023","journal-title":"eJHaem"},{"key":"10.1016\/j.autrev.2025.103895_bb0200","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/j.clml.2019.07.442","article-title":"Ibrutinib is effective in refractory type II cryoglobulinemia","volume":"19","author":"Barot","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.autrev.2025.103895_bb0205","doi-asserted-by":"crossref","first-page":"IJH44","DOI":"10.2217\/ijh-2022-0006","article-title":"Beyond monoclonal gammopathy of undetermined significance, clinical spectrum of immunoglobulin M gammopathy: a case series with focus on the diagnostic and management challenges","volume":"12","author":"Ashruf","year":"2023","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.autrev.2025.103895_bb0210","first-page":"42","article-title":"Light chain myeloma precipitating cryoglobulinemic vasculitis","volume":"13","author":"Saeed","year":"2023","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"Suppl. 126","key":"10.1016\/j.autrev.2025.103895_bb0215","first-page":"10","article-title":"One year in review 2020: comorbidities, diagnosis and treatment of primary Sj\u00f6gren\u2019s syndrome","volume":"38","author":"Manfr\u00e8","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0220","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2007-10-119974","article-title":"Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph consortium","volume":"111","author":"Ekstr\u00f6m Smedby","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103895_bb0225","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.3390\/jcm11154272","article-title":"Risk of Cancer in connective tissue diseases in Northeastern Italy over 15 years","volume":"11","author":"Treppo","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0230","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","article-title":"Lymphoma and other malignancies in primary Sjogren\u2019s syndrome: a cohort study on cancer incidence and lymphoma predictors","volume":"65","author":"Theander","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0235","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/rheumatology\/keab939","article-title":"Clinical picture, outcome and predictive factors of lymphoma in primary Sj\u00f6gren\u2019s syndrome: results from a harmonized dataset (1981\u20132021)","volume":"61","author":"Chatzis","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0240","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1006\/bcmd.2001.0446","article-title":"Preliminary classification of nonmalignant B cell proliferation in Sj\u00f6gren\u2019s syndrome: perspectives on pathobiology and treatment based on an integrated Clinico-pathologic and molecular study approach","volume":"27","author":"De Vita","year":"2001","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0245","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.1780390508","article-title":"Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"39","author":"Tzioufas","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103895_bb0250","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/ard.60.11.1007","article-title":"Lymphomas complicating Sjogren\u2019s syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells","volume":"60","author":"Mariette","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0255","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/rheumatology\/ker407","article-title":"Cryoglobulinaemia related to Sjogren\u2019s syndrome or HCV infection: differences based on the pattern of bone marrow involvement, lymphoma evolution and laboratory tests after parotidectomy","volume":"51","author":"De Vita","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0260","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1093\/rheumatology\/kez052","article-title":"Lymphomas complicating primary Sj\u00f6gren\u2019s syndrome: from autoimmunity to lymphoma","volume":"60","author":"Nocturne","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0265","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2018.08.007","article-title":"Lymphomagenesis in Sj\u00f6gren\u2019s syndrome: predictive biomarkers towards precision medicine","volume":"18","author":"Goules","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103895_bb0270","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/rheumatology\/keac470","article-title":"Predicting lymphoma in Sj\u00f6gren\u2019s syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording","volume":"62","author":"De Vita","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0275","doi-asserted-by":"crossref","first-page":"e693","DOI":"10.1016\/S2665-9913(24)00183-8","article-title":"Identification and evolution of predictors of Sj\u00f6gren\u2019s disease-associated mucosa-associated lymphoid tissue lymphoma development over time: a case-control study","volume":"6","author":"Goules","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102062","article-title":"Mortality risk factors in primary Sj\u00f6gren syndrome: a real-world, retrospective, cohort study","volume":"61","author":"Brito-Zer\u00f3n","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.autrev.2025.103895_bb0285","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/01.md.0000157398.37679.47","article-title":"Circulating monoclonal immunoglobulins in Sj\u00f6gren syndrome: prevalence and clinical significance in 237 patients","volume":"84","author":"Brito-Zer\u00f3n","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2025.103895_bb0290","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jaut.2012.01.010","article-title":"Monoclonal gammopathy related to Sj\u00f6gren syndrome: a key marker of disease prognosis and outcomes","volume":"39","author":"Brito-Zer\u00f3n","year":"2012","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2025.103895_bb0295","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10067-024-06890-y","article-title":"Sj\u00f6gren\u2019s disease activity associates with cardiovascular disease and monoclonal gammopathy: a university cohort study of disease activity and comorbidities","volume":"43","author":"Bohman","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0300","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0005-2744(75)90215-6","article-title":"Purification and some enzymatic properties of the chitosanase from Bacillus R-4 which lyses Rhizopus cell walls","volume":"410","author":"Tominaga","year":"1975","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2025.103895_bb0305","doi-asserted-by":"crossref","first-page":"1130686","DOI":"10.3389\/fonc.2023.1130686","article-title":"Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sj\u00f6gren\u2019s syndrome patients through immunogenetics","volume":"13","author":"Kolijn","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.autrev.2025.103895_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2023.105686","article-title":"Molecular B-cell clonality assay in minor salivary glands as a useful tool for the lymphoma risk assessment in Sj\u00f6gren\u2019s syndrome","volume":"91","author":"Benyamine","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2025.103895_bb0315","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1573397113666170103152537","article-title":"Coexistance of amyloidosis and primary Sj\u00f6gren\u2019s syndrome: an overview","volume":"14","author":"Hernandez-Molina","year":"2018","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.autrev.2025.103895_bb0320","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1016\/S2665-9913(23)00340-5","article-title":"Identification of distinct subgroups of Sj\u00f6gren\u2019s disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts","volume":"6","author":"Nguyen","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0325","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000246814","article-title":"Characterization of the amyloid fibril from primary localized cutaneous nodular amyloidosis associated with Sj\u00f6gren\u2019s syndrome","volume":"189","author":"Inazumi","year":"1994","journal-title":"Dermatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0330","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.3390\/ijms24087378","article-title":"Localized cutaneous nodular amyloidosis: a specific cutaneous manifestation of Sj\u00f6gren\u2019s syndrome","volume":"24","author":"Llamas-Molina","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103895_bb0335","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1440-1843.2010.01772.x","article-title":"Pulmonary amyloidosis in Sjogren\u2019s syndrome: a case report and systematic review of the literature","volume":"15","author":"Rajagopala","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2025.103895_bb0340","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0345","doi-asserted-by":"crossref","first-page":"kev257","DOI":"10.1093\/rheumatology\/kev257","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren\u2019s syndrome: the BELISS open-label phase II study","author":"De Vita","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0350","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren\u2019s syndrome: results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0355","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sj\u00f6gren\u2019s syndrome","volume":"7","author":"Mariette","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.autrev.2025.103895_bb0360","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2021-222054","article-title":"Development and preliminary validation of the Sj\u00f6gren\u2019s tool for assessing response (STAR): a consensual composite score for assessing treatment effect in primary Sj\u00f6gren\u2019s syndrome","volume":"81","author":"Seror","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0365","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.1016\/S2665-9913(21)00122-3","article-title":"Composite of Relevant Endpoints for Sj\u00f6gren\u2019s Syndrome (CRESS): development and validation of a novel outcome measure","volume":"3","author":"Arends","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0370","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/art.42772","volume":"76","author":"Pontarini","year":"2024","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103895_bb0375","doi-asserted-by":"crossref","first-page":"e703","DOI":"10.1016\/S2665-9913(24)00198-X","article-title":"Treatment modalities of marginal zone lymphoma and overall survival, haematological response, and underlying Sj\u00f6gren\u2019s disease activity: a multicentre, retrospective, observational study","volume":"6","author":"Rocca","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0380","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S0140-6736(24)01211-X","article-title":"Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sj\u00f6gren\u2019s disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study","volume":"404","author":"Fisher","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.autrev.2025.103895_bb0385","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren\u2019s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0390","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103895_bb0395","doi-asserted-by":"crossref","first-page":"iii15","DOI":"10.1093\/rheumatology\/keaf142.025","article-title":"OA25Efficacy and safety of nipocalimab, an anti-FcRn monoclonal antibody, in primary Sjogren\u2019s disease: results from a Phase 2, multicenter, randomized, placebo-controlled, double-blind study (DAHLIAS)","volume":"64","author":"Gottenberg","year":"2025","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0400","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard-2023-224691","article-title":"Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial","volume":"83","author":"D\u00f6rner","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0405","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/ard-2023-224999","article-title":"Obinutuzumab in patients with Sjogren\u2019s disease immunised against rituximab","volume":"83","author":"Pezot","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0410","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003464","article-title":"Efficacy of daratumumab in refractory primary Sj\u00f6gren disease","volume":"9","author":"Nocturne","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103895_bb0415","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001248","article-title":"Monoclonal gammopathy in systemic lupus erythematosus is associated with distinctive clinical course, malignancy and mortality rate: a single-centre retrospective cohort study","volume":"11","author":"Siwiec-Kozlik","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0420","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/0961203307079045","article-title":"Monoclonal gammopathy in systemic lupus erythematosus","volume":"16","author":"Ali","year":"2007","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2025.103895_bb0425","doi-asserted-by":"crossref","first-page":"141","DOI":"10.25122\/jml-2023-0314","article-title":"SLE and multiple myeloma: an underlooked link? A review of case reports from the last decade","volume":"17","author":"Desai","year":"2024","journal-title":"J Med Life"},{"key":"10.1016\/j.autrev.2025.103895_bb0430","first-page":"1","article-title":"Haematological malignancies in systemic sclerosis patients: case reports and review of the world literature","volume":"2017","author":"Colaci","year":"2017","journal-title":"Case Rep Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0435","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.canep.2013.04.014","article-title":"The risk of cancer development in systemic sclerosis: a meta-analysis","volume":"37","author":"Zhang","year":"2013","journal-title":"Cancer Epidemiol"},{"key":"10.1016\/j.autrev.2025.103895_bb0440","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0445","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.autrev.2014.08.016","article-title":"Systemic sclerosis and prevalence of monoclonal immunoglobulin","volume":"13","author":"Trad","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103895_bb0450","doi-asserted-by":"crossref","first-page":"m1067","DOI":"10.1136\/bmj.m1067","article-title":"Advances in the diagnosis and management of IgG4 related disease","volume":"369","author":"Lanzillotta","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2025.103895_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2019.07.004","article-title":"B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease","volume":"145","author":"Della-Torre","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103895_bb0460","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ajh.26240","article-title":"POEMS syndrome: 2021 update on diagnosis, risk-stratification, and management","volume":"96","author":"Dispenzieri","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2025.103895_bb0465","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0470","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1182\/blood-2023-186736","article-title":"Clonal bone marrow plasma cells are common in patients with Vexas syndrome","volume":"142","author":"Dulau-Florea","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103895_bb0475","doi-asserted-by":"crossref","first-page":"e70064","DOI":"10.1002\/acr2.70064","article-title":"Unveiling VEXAS syndrome: when skin manifestations and monoclonal gammopathy precede myeloid-lineage hematologic abnormality","volume":"7","author":"Di Centa","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0480","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11926-017-0673-5","article-title":"Schnitzler Syndrome: a Review","volume":"19","author":"Gusdorf","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2025.103895_bb0485","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/BOR.0000000000000118","article-title":"Scleromyxedema","volume":"26","author":"Hummers","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2025.103895_bb0490","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/joim.13169","article-title":"Systemic amyloidosis from a (AA) to T (ATTR): a review","volume":"289","author":"Muchtar","year":"2021","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0495","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1038\/s41467-024-49186-0","article-title":"Clonal associations between lymphocyte subsets and functional states in rheumatoid arthritis synovium","volume":"15","author":"Dunlap","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2025.103895_bb0500","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/art.40654","article-title":"Prevalence and characteristics of persistent clonal T cell large granular lymphocyte expansions in rheumatoid arthritis: a comprehensive analysis of 529 patients","volume":"70","author":"Schwaneck","year":"2018","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2025.103895_bb0505","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0002-9343(89)90300-8","article-title":"Prevalence of granual lymphocyte proliferation in patients with rheumatoid arthritis and neutropenia","volume":"86","author":"Saway","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0510","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.869205","article-title":"Intersection between large granular lymphocyte Leukemia and rheumatoid arthritis","volume":"12","author":"Moosic","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.autrev.2025.103895_bb0535","first-page":"12","article-title":"Monoclonal gammopathy and rheumatic diseases","volume":"39","author":"Raposo","year":"2014","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.autrev.2025.103895_bb0540","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","article-title":"Interleukin-6 in human multiple myeloma","volume":"85","author":"Klein","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2025.103895_bb0545","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103895_bb0550","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes?","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.autrev.2025.103895_bb0555","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","article-title":"The role of tumor necrosis factor \u03b1 in the pathophysiology of human multiple myeloma: therapeutic applications","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.autrev.2025.103895_bb0560","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1002\/ijc.32891","article-title":"Targets of biologic disease-modifying antirheumatic drugs and risk of multiple myeloma","volume":"147","author":"Calip","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.autrev.2025.103895_bb0565","doi-asserted-by":"crossref","first-page":"65","DOI":"10.18632\/oncotarget.28547","article-title":"Preclinical and clinical evaluation of the Janus kinase inhibitor ruxolitinib in multiple myeloma","volume":"15","author":"Del Dosso","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.autrev.2025.103895_bb0570","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/rheumatology\/kead187","article-title":"Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry","volume":"63","author":"Faganello","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103895_bb0575","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.autrev.2025.103895_bb0580","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2025.103895_bb0585","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10787-021-00863-2","article-title":"Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases","volume":"29","author":"Khalesi","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.autrev.2025.103895_bb0590","series-title":"The BAFF-APRIL System in Cancer Cancers","first-page":"1791","volume":"15","author":"Ullah","year":"2023"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T23:52:30Z","timestamp":1763769150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":118,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1568997225001569"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103895","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monoclonal Gammopathy of Rheumatologic Significance (MGRhS): a systemic vision of clonal disorders with multiple organ involvement","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103895","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103895"}}